Frantz EyeCare reports 98% of Light Adjustable Lens patients achieved refractive accuracy within ±0.50 D of target, exceeding published national cataract surgery benchmarks.
|Articles|April 1, 2003
Should a prostaglandin agent be used as initial monotherapy?
Not long after topical timolol was introduced in 1978, it became one of the most widely prescribed glaucoma medications in the world. Although timolol is considered to be the most significant therapeutic advance in the medical treatment of glaucoma in the 20th century, the 1994 introduction of prostaglandin analogs for glaucoma treatment in Japan marked the end of timolol's domination.
Advertisement
Advertisement
Related to this article
In this Q&A, Ping Moore, OD, covers emerging dry eye therapies, from selenium sulfide to next-gen cyclosporine, and how subtype-guided care shapes treatment choices.
Ophthalmology is projected to face one of the steepest physician shortages of any subspecialty by 2038.
Two investigational pipeline therapies take aim at the root causes of dry eye disease
Dry eye care pivots to root-cause diagnosis and personalized biologics/devices,
Cataract surgery becomes refractive: learn how IOL choices and preop counseling across distance, intermediate and near turn 20/20 into 20/happy.
Findings from the third annual State of Dry Eye survey link symptom management to quality of life gains, including lower anxiety and improved self-confidence.
June brings FDA clearance for Lumvoa, key retina and glaucoma trials, device deals, and hard truths on AI performance in eye care.
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
Duravyu misses noninferiority end point in phase 3 LUCIA wet AMD trial
2
Beyond slowing atrophy: Optogenetic therapy targets vision lost to GA
3
FDA approves phentolamine ophthalmic solution 0.75% (Ryzumvi) for presbyopia
4
SpyGlass Pharma's BIM-IOL System holds 37% IOP reduction at 4 years in first-in-human trial
5